Within the healthcare sector, research and development activities play an imperative role in the discovery of new treatments. The prevalence of neurotrophic keratitis is relatively low due to which, there were no approved drugs in the market to treat the rare eye disease. However, over the past decade, there were significant investments for the development and discovery of drugs that could potentially treat the rare eye disease. Progress in biotechnology has enabled the development of new biological treatments that address neurotrophic keratitis. Moreover, research and development activities have received an added push over the past few years, due to a steady rise in the number of neurotrophic keratitis.
While developed regions such as North America and Europe are likely to present lucrative opportunities for players involved in the current neurotrophic keratitis market landscape due to favorable reimbursement policies and concrete healthcare infrastructure in these regions. However, the neurotrophic keratitis market in developing regions such as Asia Pacific is expected to witness significant developments during the forecast period, due to growing government investments in healthcare and R&D. Thus, the global neurotrophic keratitis market is projected to attain a market value of US$ 324 Mn by the end of 2027.
For drug developers, apart from research and development, receiving the approval from the FDA is one of the most critical stages of the drug development process. Within the neurotrophic keratitis market, the lack of approved drugs for neurotrophic keratitis provided a window of opportunity for drug developers. Innovations and progress in the development of new drugs will continue to influence the growth of the neurotrophic keratitis market during the assessment period. In 2018, the U.S. Food and Drug Administration waved the green flag and approved Oxervate, a drug developed by an Italian pharmaceutical company, Dompé. Moreover, Oxervate, stands to remain the first-ever drug to receive the approval from the FDA for the treatment of neurotrophic keratitis. Despite having a significantly lower prevalence rate, neurotrophic keratitis can have a devastating impact on individuals suffering from this disease.
Receiving approval from the FDA is tipped to be one of the most groundbreaking developments in the current neurotrophic keratitis market, and likely to pave the way for new drugs and treatments during the forecast period. While the FDA approval marks the beginning of new drug development activities in the neurotrophic keratitis market, drug developers are also expected to invest resources to curb the adverse reactions of these drugs.
In the past few years, research and development activities have gained considerable amount of traction in the neurotrophic keratitis market. Clinical trials on different animals have revealed that corneal denervation minimizes corneo limbal stem cell function and number– a factor that could cause the development of epithelial ulcers experienced by patients suffering from neurotrophic keratitis. At present, some of the most notable treatments offered to treat neurotrophic keratitis include autologous serum eye drops, tarsorrhaphy, gold weight placement, punctual closure, and bandage contact lenses. The recombinant human nerve growth factors eye drops sub-segment segment of the drugs segment is projected to gain significant popularity in the second half of the forecast period and emerge as one of the most vital treatment types due to the growing evidence supporting the efficacy of the treatment. Some of the key parameters that are used to assess the efficacy of treatment include corneal healing, corneal sensitivity, and duration of corneal healing, among others.
Analysts’ Viewpoint
The global neurotrophic keratitis market is expected to grow at a staggering CAGR of ~17% during the forecast period. The impressive market growth will be driven by a range of factors, including rise in the number of neurotrophic keratitis cases across the world and surge in co-morbidities and risk factors. Moreover, research and development activities for the development of new treatment and drugs will continue to define the course of the market for neurotrophic keratitis during the forecast period. Drug developers and key participants in the current market landscape will eagerly anticipate obtaining the FDA approval for their drugs and treatment. While North America and Europe are expected to lead in terms of market share and value, Asia Pacific region will continue to present lucrative opportunities for market players.
The global neurotrophic keratitis market was worth US$ 91.6 Mn and is projected to reach a value of US$ 324 Mn by the end of 2027
Neurotrophic keratitis market is anticipated to grow at a CAGR of 17% during the forecast period
North America accounted for a major share of the global neurotrophic keratitis market
Neurotrophic keratitis market is driven by rise in reported cases of keratitis, increase in research & developmental activities, surge in awareness, and rise in co-morbidities & risk factors boost the growth of the market
Key players in the global neurotrophic keratitis market include Dompe farmaceutici S.p.A., Allergan, ReGenTree, LLC, Alcon, Bausch & Lomb Incorporated (Bausch Health Companies Inc.), CONTACARE, OHTO Pharmaceutical Co., Ltd., Pfizer, Inc., Neuroptika, Santen Pharmaceutical Co., Ltd., Johnson & Johnson, Grand Pharma (China) Co., Ltd., and Zhejiang CONBA Pharmaceutical Co., Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Neurotrophic Keratitis Market
4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Neurotrophic Keratitis Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Disease Prevalence & Incidence Rate globally with key countries / Region
5.2. Pipeline Analysis
5.3. Key Industry Developments
6. Global Neurotrophic Keratitis Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2027
6.3.1. Drugs
6.3.1.1. Artificial Tears
6.3.1.2. Recombinant Human Nerve Growth Factors Eye Drop
6.3.1.3. Oral Antibiotics
6.3.1.4. Bandage Contact Lens
6.3.1.5. Others
6.3.2. Surgical Intervention
6.3.2.1. Tarsorrhaphy
6.3.2.2. Amniotic Membrane Transplantation
6.3.2.3. Others
6.4. Market Attractiveness, by Treatment Type
7. Global Neurotrophic Keratitis Market Analysis and Forecast, by Stage
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Stage, 2017–2027
7.3.1. Stage I
7.3.2. Stage II
7.3.3. Stage III
7.4. Market Attractiveness Analysis, by Stage
8. Global Neurotrophic Keratitis Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Region
9. North America Neurotrophic Keratitis Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Treatment Type, 2017–2027
9.2.1. Drugs
9.2.1.1. Artificial Tears
9.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
9.2.1.3. Oral Antibiotics
9.2.1.4. Bandage Contact Lens
9.2.1.5. Others
9.2.2. Surgical Intervention
9.2.2.1. Tarsorrhaphy
9.2.2.2. Amniotic Membrane Transplantation
9.2.2.3. Others
9.3. Market Value Forecast, by Stage, 2017–2027
9.3.1. Stage I
9.3.2. Stage II
9.3.3. Stage III
9.4. Market Value Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment Type
9.5.2. By Stage
9.5.3. By Country
10. Europe Neurotrophic Keratitis Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2027
10.2.1. Drugs
10.2.1.1. Artificial Tears
10.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
10.2.1.3. Oral Antibiotics
10.2.1.4. Bandage Contact Lens
10.2.1.5. Others
10.2.2. Surgical Intervention
10.2.2.1. Tarsorrhaphy
10.2.2.2. Amniotic Membrane Transplantation
10.2.2.3. Others
10.3. Market Value Forecast, by Stage, 2017–2027
10.3.1. Stage I
10.3.2. Stage II
10.3.3. Stage III
10.4. Market Value Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment Type
10.5.2. By Stage
10.5.3. By Country/Sub-region
11. Asia Pacific Neurotrophic Keratitis Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2027
11.2.1. Drugs
11.2.1.1. Artificial Tears
11.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
11.2.1.3. Oral Antibiotics
11.2.1.4. Bandage Contact Lens
11.2.1.5. Others
11.2.2. Surgical Intervention
11.2.2.1. Tarsorrhaphy
11.2.2.2. Amniotic Membrane Transplantation
11.2.2.3. Others
11.3. Market Value Forecast, by Stage, 2017–2027
11.3.1. Stage I
11.3.2. Stage II
11.3.3. Stage III
11.4. Market Value Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment Type
11.5.2. By Stage
11.5.3. By Country/Sub-region
12. Latin America Neurotrophic Keratitis Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2027
12.2.1. Drugs
12.2.1.1. Artificial Tears
12.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
12.2.1.3. Oral Antibiotics
12.2.1.4. Bandage Contact Lens
12.2.1.5. Others
12.2.2. Surgical Intervention
12.2.2.1. Tarsorrhaphy
12.2.2.2. Amniotic Membrane Transplantation
12.2.2.3. Others
12.3. Market Value Forecast, by Stage, 2017–2027
12.3.1. Stage I
12.3.2. Stage II
12.3.3. Stage III
12.4. Market Value Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment Type
12.5.2. By Stage
12.5.3. By Country/Sub-region
13. Middle East & Africa Neurotrophic Keratitis Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2027
13.2.1. Drugs
13.2.1.1. Artificial Tears
13.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
13.2.1.3. Oral Antibiotics
13.2.1.4. Bandage Contact Lens
13.2.1.5. Others
13.2.2. Surgical Intervention
13.2.2.1. Tarsorrhaphy
13.2.2.2. Amniotic Membrane Transplantation
13.2.2.3. Others
13.3. Market Value Forecast, by Stage, 2017–2027
13.3.1. Stage I
13.3.2. Stage II
13.3.3. Stage III
13.4. Market Value Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment Type
13.5.2. By Stage
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of companies)
14.2. Market Share/Position Analysis, by Company, 2018
14.3. Company Profiles
14.3.1. Dompe farmaceutici S.p.A.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Growth Strategies
14.3.1.3. SWOT Analysis
14.3.2. Allergan
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Growth Strategies
14.3.2.3. SWOT Analysis
14.3.3. ReGenTree, LLC
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Growth Strategies
14.3.3.3. SWOT Analysis
14.3.4. Alcon
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Growth Strategies
14.3.4.3. SWOT Analysis
14.3.5. Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Growth Strategies
14.3.5.3. SWOT Analysis
14.3.6. CONTACARE
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Growth Strategies
14.3.6.3. SWOT Analysis
14.3.7. ROHTO Pharmaceutical Co., Ltd.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Growth Strategies
14.3.7.3. SWOT Analysis
14.3.8. Pfizer, Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Growth Strategies
14.3.8.3. SWOT Analysis
14.3.9. Neuroptika
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Growth Strategies
14.3.9.3. SWOT Analysis
14.3.10. Santen Pharmaceutical Co., Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Growth Strategies
14.3.10.3. SWOT Analysis
14.3.11. Johnson & Johnson
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Growth Strategies
14.3.11.3. SWOT Analysis
14.3.12. Grand Pharma (China) Co., Ltd.
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Growth Strategies
14.3.12.3. SWOT Analysis
14.3.13. Zhejiang CONBA Pharmaceutical Co., Ltd.
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Growth Strategies
14.3.13.3. SWOT Analysis
List of Tables
Table 01: Neurotrophic Keratitis Pipeline Analysis - Phase III and Phase II
Table 02: Neurotrophic Keratitis Pipeline Analysis - Phase I
Table 03: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 04: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 05: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 06: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027
Table 07: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 09: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 10: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 11: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 12: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027
Table 13: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 14: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 15: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 16: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 17: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027
Table 18: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 19: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 20: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 21: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 22: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027
Table 23: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 24: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 25: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 26: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 27: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027
Table 28: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 29: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 30: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
Table 31: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027
Table 32: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027
List of Figures
Figure 01: Global Neurotrophic Keratitis Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
Figure 02: Global Neurotrophic Keratitis Market Value (US$ Mn), by Treatment Type, 2018 (A)
Figure 03: Global Neurotrophic Keratitis Market, Top 3 Trends, 2018
Figure 04: Market Overview
Figure 05: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, 2017–2027
Figure 06: Global Neurotrophic Keratitis Market Value Share, by Treatment Type, 2018
Figure 07: Global Neurotrophic Keratitis Market Value Share, by Stage, 2018
Figure 08: Global Neurotrophic Keratitis Market Value Share, by Region, 2018
Figure 09: Global Neurotrophic Keratitis Market Value Share, by Drugs, 2018
Figure 10: Global Neurotrophic Keratitis Market Value Share, by Surgical Intervention, 2018
Figure 11: Global Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
Figure 12: Global Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
Figure 13: Global Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
Figure 14: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Drugs, 2017–2027
Figure 15: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Surgical Intervention, 2017–2027
Figure 16: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027
Figure 17: Global Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
Figure 18: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage I, 2017–2027
Figure 19: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage II, 2017–2027
Figure 20: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage III, 2017–2027
Figure 21: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027
Figure 22: Global Neurotrophic Keratitis Market Value Share Analysis, by Region, 2018 and 2027
Figure 23: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Region, 2019–2027
Figure 24: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 25: North America Neurotrophic Keratitis Market Value Share Analysis, by Country, 2018 and 2027
Figure 26: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Country, 2019–2027
Figure 27: North America Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
Figure 28: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027
Figure 29: North America Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
Figure 30: North America Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
Figure 31: North America Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
Figure 32: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027
Figure 33: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 34: Europe Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 35: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 36: Europe Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
Figure 37: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027
Figure 38: Europe Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
Figure 39: Europe Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
Figure 40: Europe Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
Figure 41: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027
Figure 42: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 43: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 44: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 45: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
Figure 46: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027
Figure 47: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
Figure 48: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
Figure 49: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
Figure 50: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027
Figure 51: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 52: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 53: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 54: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
Figure 55: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027
Figure 56: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
Figure 57: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
Figure 58: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
Figure 59: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027
Figure 60: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 61: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 62: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 63: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
Figure 64: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027
Figure 65: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
Figure 66: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
Figure 67: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
Figure 68: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027
Figure 69: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Neurotrophic Keratitis Market
